Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Budesonide/formoterol; Formoterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- 29 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Feb 2012 Actual end date Nov 2010 added as reported by ClinicalTrials.gov.
- 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History